The Food and Drug Administration (FDA) has inspected fewer pharmaceutical manufacturing facilities compared to before the COVID-19 pandemic, with foreign facilities, including those from China, seeing the largest decreases, according to a study released in December.
In 2022, the total number of inspections of drug manufacturing establishments by the FDA decreased by 79% for foreign and 35% for domestic facilities compared to 2019, before the COVID-19 pandemic, according to a study by Emily Cuddy, Yun Peng Lu and David B. Ridley using data acquired through Freedom of Information Act requests. Despite the drop in inspections, there was no corresponding decrease in imports or manufacturing, while resources allocated by the FDA toward inspections surged per inspection.
Read More